Journal News

A bridge to overcoming TRIBled prostate cancer

Connor O'Hara
Aug. 16, 2022

Prostate cancer is a leading cause of cancer-related deaths for men in the U.S., and the American Cancer Society predicts over 30,000 deaths from prostate cancer this year. Doctors use several strategies to combat this deadly disease.

Androgen, a male steroid hormone, plays a pivotal role in the initiation and progression of prostate cancer, so ablation or blocking of androgen signaling is one common treatment. The drug enzalutamide, an inhibitor of the androgen receptor, is a popular clinical choice for the treatment of prostate cancer. However, the treatment has limited efficacy.

“Enzalutamide is a popular drug, but resistance almost always develops,” researcher Jagadananda Ghosh said. “This prompted us to explore the underlying molecular mechanisms so that we can find a way to overcome this problem.”

A team led by Ghosh and Jitender Monga at the Henry Ford Health System in Detroit recently published a paper in the Journal of Biological Chemistry with news about a novel protein, Tribbles 2, or TRIB2, that scientists have found to be a functional biomarker of prostate cancer and a potential target for new, alternative therapies for enzalutamide-resistant, or ENZ-R, cancer that could extend the lives of patients.

To better understand the mechanism of ENZ-R, the team used both cell-based and animal models to characterize the expression of this protein and others related to the survival and phenotype of prostate cancer.

The pseudokinase TRIB2 regulates wing pattern and development in the fruit fly Drosophila and has analogs found across several species including humans, where it engages with intracellular signaling hubs to host a variety of growth and survival mechanisms. In a comprehensive gene array, the team found that TRIB2 is greatly overexpressed in ENZ-R prostate cells, and these cells also show elevated expression of an anti-apoptotic protein, Bcl-xL. When the team inhibited TRIB2 in the animal models using genetics and pharmacology, they saw a dramatic reduction in viable ENZ-R prostate cells and reductions in tumor volume.

This figure illustrates the over expression of TRIB2 in enzalutamide-resistant prostate cancer cells and tumors.
Ghosh et al., 2021
This figure illustrates the over expression of TRIB2 in enzalutamide-resistant prostate cancer cells and tumors.

To understand how TRIB2 promoted this drug resistance and caused these changes in survival and growth, the researchers characterized the expression of luminal cell, neuroendocrine and stemness markers. They found that cells overexpressing TRIB2 were depleted in luminal cell markers but rich in those associated with neuroendocrine and stemness phenotypes. They reproduced this result in tumor xenografts and documented using immunohistochemical staining.

“TRIB2 emerges as a new driver for trans-differentiation of prostate cancer cells from adenocarcinoma to neuroendocrine and to confer resistance to enzalutamide,” Ghosh said.

From this work, the team proposes that inhibiting AR signaling may have a negative impact on development of highly resistant and lethal prostate cancer cells. They have seen that kinase TRIB2 is not just a biomarker for ENZ-R cells but also functions in developing drug resistance. By comparing the phenotypic profile of these cells with ENZ-sensitive cells, they could identify a switch toward prostate cancer in the ENZ-R cells that display stemlike and neuroendocrine features, a potential cause of the resistance.

The dynamic plasticity of these cells in response to therapy may provide researchers with opportunity to alter treatment strategies and address this AR-independent resistance mechanism.

“We are working to dissect the regulation and role of TRIB2 using various in vivo models,” Ghosh said, “and we’re formulating strategies to interrupt the activity of TRIB2 to develop a new targeted therapy for aggressive, lethal prostate cancer.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Connor O'Hara

Connor O’Hara is a graduate student in the Department of Medicinal Chemistry at the School of Pharmacy at Virginia Commonwealth University. Outside of his research, he enjoys a tall pint at his local pub and the company of good friends. 

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

The perfect storm
Feature

The perfect storm

Dec. 6, 2023

The world has 2023 Nobel laureates Katalin Karikó, Drew Weissman and others to thank for laying a foundation for the COVID-19 vaccine decades before the pandemic.

Throw your hat in the ring!
Annual Meeting

Throw your hat in the ring!

Dec. 6, 2023

Apply to speak at Discover BMB in Chicago in 2025.

How bacteria inhibit gene expression
Journal News

How bacteria inhibit gene expression

Dec. 5, 2023

Researchers show how altering activity of the transcription factor CarD can cause downregulation and upregulation of some genes.

Where the heck did all those structures inside complex cells come from?
Feature

Where the heck did all those structures inside complex cells come from?

Dec. 3, 2023

Scientists agree that eons ago, a bacterium took up residence inside another cell and became its powerhouse, the mitochondrion. But there are competing theories about the birth of other organelles such as the nucleus and endoplasmic reticulum.

Untangling the genetics that underlie our facial features
Feature

Untangling the genetics that underlie our facial features

Dec. 2, 2023

After turning up hundreds of genes with hard-to-predict effects, some scientists are now probing the grander developmental processes that shape face geometry.

From the journals: JLR
Journal News

From the journals: JLR

Dec. 1, 2023

A safer combination therapy for liver disease. A mechanistic pathway of the pathophysiology of NASH. A novel therapeutic target for heart failure. Read about recent papers on these topics.